ELV

Rating neutralTentativeAI MemoPost-earnings T+3

Elevance Health

As of 2026-07-20/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Medicaid remediation and market-exit execution • 2027-07-15

Base target: $410 / p=50% prob

Biggest risk

The market reaction indicates that investors are prioritizing Medicaid losses and possible footprint contraction over the earnings beat. Higher government medical-cost trends, declining membership, and execution risk could keep the valuation compressed [#SEC-8K-2026-07-15] [#PR-EARNINGS-2026-07-17].

Invalidation

Break below $300 or thesis failure.

What would change my mind?

The Q2 beat, higher FY2026 adjusted EPS and cash-flow guidance, and management's 2027 growth objective support a recovery case if medical-cost trends normalize and Carelon investments improve execution [#SEC-8K-2026-07-15].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-20

Base target

$410

p=50%

Bull target

$470

p=25%

Bear target

$300

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings digestion of a strong print versus Medicaid concerns
2027 earnings-growth recovery
The Q2 beat, higher FY2026 adjusted EPS and cash-flow guidance, and management's 2027 growth objective support a recovery case if medical-cost trends normalize and Carelon investments improve execution [#SEC-8K-2026-07-15].

BearKey bullets

Consolidated operating margin declined to 3.5% from 4.9% year over year in Q2 [#SEC-8K-2026-07-15].
Government medical-cost trend pressure; the Q2 benefit expense ratio increased 80 basis points year over year [#SEC-8K-2026-07-15].
Medicaid operating-margin weakness and potential exits from additional markets.

WatchKey bullets

Medicaid remediation and market-exit execution

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $410 (p=50%)

Target spread vs base: +15% / -27%

Scenario probabilities

Bull Target: $470 (p=25%)Base Target: $410 (p=50%)Bear Target: $300 (p=25%)

Commentary

News tone is mixed: the company source confirms a Q2 beat and higher guidance [#SEC-8K-2026-07-15], while stored coverage highlights an approximately 8.5% selloff centered on Medicaid concerns [#PR-EARNINGS-2026-07-17]. Social coverage and analyst revision data are unavailable, so the positive deterministic prior is treated as a tentative recovery signal rather than confirmation of a durable re-rating. The peer comparison is limited to two relevant payer/service comparators because the remaining packet candidates are device, distributor, or provider businesses rather than direct ELV peers.

As of 2026-07-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings digestion of a strong print versus Medicaid concerns
2027 earnings-growth recovery

Scenarios

Bull Target (Scenario probability)

$470 / p=25% prob

Base Target (Scenario probability)

$410 / p=50% prob

Bear Target (Scenario probability)

$300 / p=25% prob

Analysis 2026-07-20 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-07-15
Medicaid remediation and market-exit execution
Stored earnings context reports a FY2026 Medicaid operating-margin outlook of -1.75%, an agreement to exit the D.C. Medicaid market, and possible exits from additional markets over the next 12–18 months [#PR-EARNINGS-2026-07-17]. Evidence of improving cost performance or a credible remediation path could support recovery; further deterioration would pressure the shares.
Prob 55.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-earnings digestion of a strong print versus Medicaid concerns
2026-07-31
Elevance reported Q2 adjusted EPS of $7.45, raised FY2026 adjusted EPS guidance to at least $27.00, and raised operating cash-flow guidance to at least $6.0 billion [#SEC-8K-2026-07-15] [#8-K-2026-07-15]. Stored post-earnings coverage reported an approximately 8.5% share-price decline as investors focused on Medicaid weakness [#PR-EARNINGS-2026-07-17].
Prob 65% • Move 4% • Priced-in 70%

Long-term Catalysts

Months to a year

2027 earnings-growth recovery
2027-12-31
Management stated confidence in returning to at least 12% adjusted EPS growth in 2027, supported by medical-cost management, operating investments, and Carelon capabilities [#SEC-8K-2026-07-15]. Delivery depends on stabilizing government-business medical trends and executing the Medicaid reset.
Prob 50% • Move 12% • Priced-in 45%

Risks

Consolidated operating margin declined to 3.5% from 4.9% year over year in Q2 [#SEC-8K-2026-07-15].
Government medical-cost trend pressure; the Q2 benefit expense ratio increased 80 basis points year over year [#SEC-8K-2026-07-15].
Medicaid operating-margin weakness and potential exits from additional markets.
No analyst estimate, rating, or price-target revision data is available in the packet.
The approximately 8.5% post-earnings decline shows that the raised guidance did not resolve investor concerns [#PR-EARNINGS-2026-07-17].

Peers

Symbol	Summary
CI	The strongest current-packet direct operating comparator: a scaled managed-care and health-services platform useful for judging medical-cost discipline, payer execution, and services-margin durability. It does not remove ELV-specific Medicaid exposure.
CVS	The strongest second direct comparator carried forward from the prior baseline: Aetna and pharmacy-benefit/services exposure provide a closer payer read-through than device-oriented candidates, while business-mix differences limit direct valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-20

Loading AI feed…

Symbol

Summary

The strongest current-packet direct operating comparator: a scaled managed-care and health-services platform useful for judging medical-cost discipline, payer execution, and services-margin durability. It does not remove ELV-specific Medicaid exposure.

CVS

The strongest second direct comparator carried forward from the prior baseline: Aetna and pharmacy-benefit/services exposure provide a closer payer read-through than device-oriented candidates, while business-mix differences limit direct valuation comparability.